“This is a great place to hear about the newest technologies and marketing strategies, government policies and changes in the roles of payers and consumers of medical devices." Prof. Mammone
New Brunswick, NJ (PRWEB) October 22, 2012
“Collaborative Innovation…The Next Generation of Medical Devices,” a free conference for industry and academia, will be held Nov. 15, from 9:30 a.m. to 2 p.m., at the Rutgers Student Center, 126 College Ave., New Brunswick. The sponsors are Rutgers’ Office of Technology Commercialization and the Office of Technology Transfer and Business Development at the University of Medicine and Dentistry of New Jersey [details at http://innovate.rutgers.edu .
“Rutgers is working to encourage industry and academia to collaborate in the local medical device innovation ecosystem, which provides many new products, jobs, and knowledge in the medical device field, and this conference is just one way we’re doing that,” says Rick Mammone, professor of business and engineering at Rutgers and the university’s associate vice president of innovation. “The conference will be a great place to hear about the newest technologies but also the latest marketing strategies, government policies and changes in the roles of payers and consumers of medical devices.”
Mammone holds numerous patents and has been an entrepreneur for years, beginning with a security technology company he started, developed and sold more than a decade ago. His latest venture is a medical device startup located in Piscataway, N.J.
The keynote speaker is Harlan Weisman, M.D., former Chief Science and Technology Officer, Medical Devices & Diagnostics at Johnson & Johnson. He served as chairman of J&J’s Worldwide R&D Council and was company group chairman, Research & Development, Pharmaceuticals. Weisman is on the Board of Governors of the Patient-Centered Outcomes Research Institute established by Congress as part of the Patient Protection and Affordable Care Act of 2010; a Fellow of the American Heart Association; and a member of the American College of Physicians, the American Federation for Clinical Research, the American Medical Association, and the New Jersey Medical Society.
A panel discussion on “Medical Device Industry Trends, Technology Pipeline, and Future Directions,” moderated by Weisman, follows his keynote.
Rutgers President Robert L. Barchi, M.D., a neuroscientist, clinical neurologist, and educator, will speak at 11 a.m. He will be introduced by Kenneth Breslauer, Ph.D., Linus C. Pauling Professor of Chemistry and Chemical Biology, dean and vice president for life and health sciences.
Rutgers faculty working on relevant research will make presentations following an introduction by Linda Brzustowicz, M.D., chair of genetics and acting senior associate vice president for research and economic development. Kathleen Scotto, Ph.D., vice president for research and dean of the Graduate School of Biomedical Sciences at UMDNJ will introduce UMDNJ researchers.
A networking and poster session will start at 12:45 p.m., coinciding with a buffet lunch. This is a forum to explore next generation technologies and interact with industry experts who can provide services to advance the commercialization of medical devices, regardless of a technology's stage of development. The event is intended for business development professionals, management and senior level executives, venture capitalists, angel investors, startups, early stage companies, vendors and service providers, medical device manufacturers, research scientists, and students.
Poster applications must be submitted by Nov. 5. Space is available for exhibitors by advance request. The event is free but advance registration is required through http://innovate.rutgers.edu.
Rutgers’ Office of Technology Commercialization is part of the Office of the Vice President for Research and Economic Development, which promotes excellence in research at Rutgers. Research is fundamental to the university’s overall mission and enhances its education and service missions. Research also contributes to economic development. Rutgers increasingly is engaged in commercialization of research through the transfer of new technologies to industry, contributing to economic development in New Jersey and nationally. From the discovery of streptomycin — the first cure for tuberculosis — to the technology behind Ask.com, Rutgers continues to make a tremendous impact in the commercial world.